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MiR-137-derived polygenic risk: effects on cognitive
performance in patients with schizophrenia and controls
D Cosgrove1, D Harold2, O Mothersill1, R Anney2,3, MJ Hill3, NJ Bray3, G Blokland4,5,6, T Petryshen4,5,6, The Wellcome Trust Case Control
Consortium, A Richards7, K Mantripragada7, M Owen7, MC O’Donovan7, M Gill2, A Corvin2, DW Morris1 and G Donohoe1
Variants at microRNA-137 (MIR137), one of the most strongly associated schizophrenia risk loci identiﬁed to date, have been
associated with poorer cognitive performance. As microRNA-137 is known to regulate the expression of ~ 1900 other genes,
including several that are independently associated with schizophrenia, we tested whether this gene set was also associated with
variation in cognitive performance. Our analysis was based on an empirically derived list of genes whose expression was altered by
manipulation of MIR137 expression. This list was cross-referenced with genome-wide schizophrenia association data to construct
individual polygenic scores. We then tested, in a sample of 808 patients and 192 controls, whether these risk scores were associated
with altered performance on cognitive functions known to be affected in schizophrenia. A subgroup of healthy participants also
underwent functional imaging during memory (n= 108) and face processing tasks (n= 83). Increased polygenic risk within the
empirically derived miR-137 regulated gene score was associated with signiﬁcantly lower performance on intelligence quotient,
working memory and episodic memory. These effects were observed most clearly at a polygenic threshold of P= 0.05, although
signiﬁcant results were observed at all three thresholds analyzed. This association was found independently for the gene set as a
whole, excluding the schizophrenia-associated MIR137 SNP itself. Analysis of the spatial working memory fMRI task further
suggested that increased risk score (thresholded at P= 10− 5) was signiﬁcantly associated with increased activation of the right
inferior occipital gyrus. In conclusion, these data are consistent with emerging evidence that MIR137 associated risk for
schizophrenia may relate to its broader downstream genetic effects.
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INTRODUCTION
Genome-wide association studies (GWAS) have identiﬁed sig-
niﬁcant associations between schizophrenia (SZ) and multiple
single nucleotide polymorphisms (SNPs) located within or near to
the microRNA-137 (MIR137) host gene on chromosome 1. In the
most recent and largest SZ GWAS1 the SNP rs1702294, located
intronically to MIR137,2 was identiﬁed as the second highest SZ-
associated variant. This SNP is in high linkage disequilibrium (LD)
with MIR137 variants previously identiﬁed in smaller GWAS3 such
as rs1622579 (r2 = 0.99)4 and rs1198588 (r2 = 0.8).4,5 In line with the
proposed inﬂuence of microRNA-137 (miR-137) on proliferation,
migration and maturation of neural cells,6–8 mechanisms impor-
tant to the cognitive process, one of three intronic variants in high
LD identiﬁed in this region (rs1625579) has been associated with a
number of cognitively relevant phenotypes. These include lower
performance in verbal episodic memory and vigilant attention,9
altered fronto-amygdala connectivity during a face processing
task10 and decreased white matter integrity,11,12 although a
number of other studies have reported conﬂicting ﬁndings, with
no effects of the MIR137 risk allele13,14 on brain structure.
SZ GWAS to date suggest that the disorder is likely to be highly
polygenic, involving a combination of both common risk variants
of small effects, such as MIR137, and rare variants of larger effects.
Modeling or quantifying this polygenic risk is therefore important,
both for the broader illness phenotypes, and for speciﬁc illness
dimensions related to functional outcomes, such as cognitive
deﬁcits. It is interesting to note that miR-137 is known or predicted
to regulate hundreds of other genes,15 many of which are
independently risk loci for SZ.3,16 In vitro studies have suggested
that miR-137 targets include BDNF, ZNF804A, TCF4, and
CACNA1C,17–21 variants that have been shown to impact on both
cognitive performance and cortical activity by our own group and
others.13,22–26 Because miR-137’s downstream regulatory targets
include loci that are independently associated with both SZ risk
and with cognitive deﬁcits, it is possible that miR-137’s regulation
of these genes may also contribute to SZ-associated deﬁcits in
cognition, in addition to the MIR137 loci’s direct effects on
cognition.
The purpose of the present study was to investigate the
polygenic effects on cognition of variants within genes that are
downstream targets of miR-137. This was based on a previous
study by Hill et al.,15 which, through miR-137 manipulation
(upregulation and inhibition), assessed genome-wide transcrip-
tional changes in a human neural progenitor cell line. This was
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carried out in order to elucidate pathways through which genetic
disruption of miR-137 may increase SZ susceptibility. As dis-
turbances in cognition are a cardinal feature of SZ, we
investigated whether polygenic risk in this gene set explained
variation in neuropsychological performance in patients and
healthy participants. A key goal for this analysis was to estimate
whether the variance explained by this downstream polygenic
burden was independent to that explained by the single most
robustly associated MIR137 SNP, rs1702294. Our hypothesis was
that a higher polygenic burden within the empirically derived
miR-137 regulated gene score, excluding the rs1702294 SNP,
would be associated with increased cognitive deﬁcits in a sample
of healthy participants and patients with psychosis.
MATERIALS AND METHODS
Participants
In total, 808 cases and 192 healthy participants completed a full
neuropsychological assessment battery and had full genome-wide SNP
data available.1 Cases consisted of n= 585 clinically stable patients with a
diagnosis of SZ and schizoaffective disorder (SZA), which we refer to as
‘narrow-sense’ psychosis, and an additional n= 223 patients diagnosed
with bipolar disorder with psychotic features, major depressive disorder
with psychotic features, delusional disorder, or psychosis not otherwise
speciﬁed who combined with SZ/SZA patients to form a ‘broad-sense’
psychosis group. Patients were diagnosed by trained psychiatrists using
the Structured Clinical Interview for DSM-IV Axis I Diagnosis.27 Inclusion
criteria required participants to be clinically stable at time of cognitive
assessment, aged between 18 and 65 years, no history of co-morbid
psychiatric disorder, no substance abuse in the preceding 6 months, no
prior head injury with loss of consciousness, no history of seizures, and
with Irish ancestry (all four grandparents born in Ireland). Healthy
participants were recruited from the general population through local
media advertisements. All were aged between 18 and 65 years and had
Irish-born paternal and maternal grandparents, and satisﬁed, on the basis
of clinical interview, the criteria of having no history of major mental health
problems, intellectual disability or acquired brain injury, and no substance
abuse in the preceding 6 months. Exclusion criteria also included having a
ﬁrst-degree relative with a history of psychosis. All clinical and
neuropsychological assessments were conducted in accordance with the
relevant ethics committees’ approval for the six sites at which this data was
collected, and all participants provided written informed consent.
Cognitive assessment
A full neuropsychological assessment designed to evaluate the cognitive
deﬁcits typically reported in SZ (general cognitive ability, memory function,
attention, and social cognition) was administered to each participant.
Selected subtests (Vocabulary, Similarities, Block Design, and Matrix
Reasoning) of the Wechsler Adult Intelligence Scale, 3rd Edition (WAIS
III)28 were used to measure general cognitive function. The Logical Memory
(LM) I and II and Faces I and II subtests from the Wechsler Memory Scale,
3rd Edition (WMS III)29 were used to assess episodic and visual memory.
Working memory was assessed using the Spatial Working Memory (SWM)
subtest from the Cambridge Automated Neuropsychological Test Battery30
and Letter-Number Sequencing from the WMS III. Attentional control
was assessed using the Continuous Performance Task (CPT) identical
pairs version31 and the Sustained Attention to Response Task (SART).32
In addition to neuropsychological assessment, this study included
measures of two aspects of social cognition—theory of mind (ToM)
(frequently altered among patients with SZ and previously associated with
MIR137(ref. 33)) and attributional style. ToM is the ability to attribute mental
states—beliefs, intents, desires, pretending, knowledge and so on—to
oneself and others and to understand that others have beliefs, desires,
intentions and perspectives that are different from one's own, and is
estimated using the Reading the Mind in the Eyes Task34 and the Hinting
Task.35 Attributional style refers to the pervasive tendency to explain
personally signiﬁcant events in a particular manner.36 Consistency in
cognitive assessment was assessed across sites by an independent
researcher marking a number of patients assessed at each site.
Genotyping
Genotyping was conducted on DNA extracted from whole blood or saliva.
Full GWAS data were available for all samples. A proportion of samples
were genotyped with an Affymetrix 6.0 chip (Santa Clara, CA, USA; as part
of the WTCCC2,37 referred to as Sample A) and the remainder on the
Illumina HumanCoreExome chip (San Diego, CA, USA; referred to as
Sample B). SNPs were excluded on the basis of MAFo0.1%, SNP
missingness ⩽ 2%, and Hardy–Weinberg equilibrium P⩽ 10− 6. Imputation
was carried out on these data sets separately using 1000 Genomes Phase I
integrated haplotypes (Dec 2013 release) and IMPUTE2 to give ~ 10 million
SNPs genome-wide per sample.
Polygene score
We began by constructing the miR-137 downstream pathway based on the
set of 1016 genes whose expression was identiﬁed as being altered by
miR-137 manipulation in the study by Hill et al.,15 831 of these genes could
be unambiguously mapped to the autosomes and this gene set was used
to generate polygene scores. We then cross-referenced with unweighted
P-values from the PGC2 2014 GWAS1 for variants within 20 kb of each gene
in this set without LD-pruning (scores with and without pruning were
highly correlated). We next deﬁned three arbitrary threshold values based
on the PGC threshold values (Po10− 5, Po0.05, and Po0.5) to generate
three polygene risk score values for analysis. Using these thresholds, 1020,
20 920 and 89 102 SNPs were included in the analysis, respectively. Finally,
each participant was then given a weighted polygene score based on the
number of risk alleles they carried within this gene list at the given gene
threshold, weighted by the log of the SZ-association odds ratio from the
PGC2. Genes used in this process are found in the Supplementary
Information.
Statistical analysis: neuropsychological tests and polygene scores
Data were inspected for heteroscedasticity, and outliers,38 which were
excluded from analysis. To estimate polygene effects on cognitive deﬁcits
associated with SZ (intelligence quotient (IQ), memory, attentional control
and social cognition) linear regression analyses were performed using IBM
SPSS Statistics,39 with age and gender entered as variables of no interest,
and test score as the dependent variable. To take into account potential
differences in results between Sample A and B due to the two differing
genotyping platforms used, a linear regression was performed separately
in each sample (those genotyped using Affymetrix and those with
Illumina). Results from these were then meta-analyzed using the inverse
variance method.40 In the inverse variance method, the weight given to
each sample is chosen to be the inverse of the variance of the effect
estimate (that is, one over the square of its standard error). This minimizes
the imprecision of the pooled effect estimate. An estimate of sample
heterogeneity and signiﬁcance of such is shown in Supplementary Table 1
(I2). To maximize power to detect differences, we carried out our analysis
on the full dataset of all cases and controls (n= 1000). We then followed
any signiﬁcant results in the patient only groups (both the broad psychosis
group (n= 808) and narrow psychosis group (patients with SZ and
schizoaffective disorder only (n= 585)) to conﬁrm the direction of effects in
these groups (Supplementary Tables 2 and 3). As the meta-analyses
showed little evidence of heterogeneity of results in Sample A and B
despite the differing genotype platforms, the sample was analyzed as a
whole to provide an estimate of effect size provide r2 and standardized β
values (Supplementary Table 4). A post hoc power calculation estimated41
that n= 988 has 0.88 power to detect a very conservative polygene score
effect of r2 = 0.01, with α=0.05, although there are certain caveats to this
type of calculation.42
Functional MRI
A subgroup of the healthy participants in this study (all right handed) had
also undergone functional imaging during two cognitive tasks. One
hundred eight participants completed a spatial working memory task and
83 had completed a facial processing task, with tasks and acquisition
parameters as described by us previously.10,33,43–45 The task can be
summarized as follows.
Spatial working memory task. This block design task was presented using
Presentation software (Neurobehavioral Systems, Albany, CA, USA).
Participants were asked if a white dot was in the same spatial location
as a red circle (Supplementary Figure 1) during three conditions. In the
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baseline condition the white dot and red circle both appear at the same
time. In the 1-dot condition, the white dot and red circle are separated by a
3- s delay. Finally, in the 3-dot condition, 3 white dots and a red circle are
presented, separated by a 3- s delay. Task accuracy and reaction time were
also measured.
Out of 108 participants, there were 3 missing this behavioral data that
were excluded from fMRI analysis, and one participant was excluded due
to an error with the task that caused it to run for several seconds after the
scan ﬁnished. Two additional participants were excluded from analysis due
to movement and 16 were excluded from all analysis due to low-quality
MRI data. This left a ﬁnal sample of 86 healthy participants.
The beginning of the spatial working memory task was synchronized to
the ﬁrst transistor-transistor logic (TTL) pulse sent from the MRI scanner at
the start of the sequence. However, for a minority of participants the start
of the task was not synchronized to the TTL pulse due to an experimental
error; for these individuals the task was run manually at the start of the
sequence. Due to the block design nature of this task, any small
discrepancies in timing resulting from this error are unlikely to affect
results.
Face processing task. Developed by Grosbras et al.,46 participants (n= 83)
watched a series of 2-s to 5-s black and white videos of faces, which started
from a neutral expression, and then turned into an angry expression or
neutral expression, interspersed with a control condition consisting of
video clips of black and white concentric circles expanding and
contracting. Blocks of video clips lasted 18- s, with 4–7 video clips
presented per block. Overall, there were 19 blocks: 5 blocks of neutral face
videos, 5 blocks of angry face videos and 9 control condition blocks (every
second block was a control block). To make sure that individuals had paid
attention to the videos, they performed a face recognition test after
scanning. In this test, 5 stil-color pictures of faces were presented and
participants were asked to determine whether these matched faces seen
during the task. Six participants were excluded as they scored less than 4/5
correct answers or were missing data for the face recognition task. One
face processing participant was excluded from analysis due to excessive
movement and 5 participants were excluded due to low-quality MRI data
and/or signiﬁcant artefacts, resulting in a ﬁnal sample of 70 participants.
Imaging pre-processing and statistical analysis. Spatial pre-processing and
statistical analysis of MRI data was performed using Statistical Parametric
Mapping (SPM8, revision 4290, http://www.ﬁl.ion.ucl.ac.uk/spm/software/
spm8/) and MATLAB R2011b (v7.13; http://www.mathworks.co.uk/). Func-
tional images were realigned to the mean functional image, normalized to
MNI (Montreal Neurological Institute) space with a voxel size of
3 × 3× 3 mm3 and smoothed using a 10 mm FWHM (full-width at half
maximum) isotropic Gaussian ﬁlter. After spatial pre-processing, graphical
plots of the estimated time series of translations and rotations were
inspected for excessive motion, which we deﬁned as more than 3 mm
translation and/or 3° rotation.
For the spatial working memory task, statistical analysis was performed
using a general linear model (GLM) with two contrasts: spatial working
memory (1 dot and 3 dots versus baseline), and increased spatial working
memory load (3 dots41 dot). For the face processing task, three task
conditions (angry faces, neutral faces and baseline) and four contrasts
consistent with our examination of neural activity associated with this task
in SZ patients:33 Neutral faces versus baseline, angry faces versus baseline,
all faces (angry and neutral) versus baseline, and angry faces versus
neutral faces.
Participants’ contrast maps were entered into a second-level analysis
to investigate effects of MIR137 network on neural activity (multiple
regression analysis with the empirically derived miR-137 regulated gene
score as covariate of interest). This multiple regression analysis was
performed for the empirically derived MIR137 gene score at the P=10− 5,
P= 0.05 and P= 0.5 levels. Results were examined at a Po0.001
(uncorrected) level and clusters were considered statistically signiﬁcant
at a Po0.05 level, family-wise error (FWE) corrected for multiple
comparisons across the whole brain at the cluster level. For each of these
clusters, MNI coordinates of signiﬁcant maxima were entered into the
Anatomy toolbox in SPM8 (refs 47–49) and probable anatomical regions
were identiﬁed using the AllAreas_v18_MPM atlas.
RESULTS
Participant demographics: neuropsychological tests
Patient demographic information appears in Table 1. In all
cognitive tests, healthy participants performed better than the
patient groups. An ANOVA found that the miR-137 polygene
scores differed signiﬁcantly between diagnosis groups at each
threshold. Predictably, patients showed higher polygene scores
than healthy participants. A post hoc Tukey test indicated that the
polygene scores for each patient group (narrow and broad sense)
was signiﬁcantly different from the control group (Po0.001) but
not from each other.
Poorer performance on measures of IQ, memory, and attention
were each found to be associated with higher miR-137 polygene
scores at all P-value thresholds. When participants were combined,
signiﬁcant ﬁndings were found across all three polygene thresh-
olds in domains of IQ, episodic memory, visual memory and
working memory (Table 2). As hypothesized, performance on
these neuropsychological measures decreased as polygene score
increased. The most markedly signiﬁcant domain was for
declarative memory functioning. Multiple declarative memory
subtests (the logical memory [immediate/delayed] and faces
subtests [immediate/delayed] of the WMS III) were highly
signiﬁcant at each score threshold, surviving a stringent Bonfer-
roni correction for the ﬁve cognitive domains analyzed. In
contrast, the analysis of the single miR-137 risk SNP rs1702294
only showed signiﬁcant inﬂuence on three domains: IQ, attention,
and a ToM measure (Table 3; P-values ranging from P= 0.042 to
P= 0.007).
As a post hoc analysis, when only patients were considered (and
not controls), the same general pattern of results were observed
as for the full group, with the relationship between higher
polygene scores and lower test accuracy remaining signiﬁcant at
the P= 10− 5 threshold, and nominally signiﬁcant at the P= 0.05
threshold. Similarly, when the effects of rs1702294 were
considered in patients only, nominal effects of the risk allele on
poorer general cognitive ability and memory ability remained.
Finally, when only SZ/SZA patients (‘narrow sense psychosis’) were
analyzed, the same direction of results was also observed for both
the polygene (Supplementary Tables 2 and 3) and single SNP
analysis (Table 3). The effects of polygene risk on cognitive test
performance were broader than that seen for the rs1702294 SNP
alone (Supplementary Table 4). This was the case across each of
the whole, broad psychosis and narrow psychosis samples.
Table 1. Participant demographic and genotype information – neuropsychological test sample
Variable Whole sample Broad psychosis Narrow psychosis (SZ/SZA) Healthy participants
N 1000 808 585 192
Age, mean (s.d.) 41.40± 12.74 42.88± 12.46 42.07± 12.54 35.20± 12.04
Female sex, % 37.7 34.4 29.9 51.6
WAIS FSIQ, mean (s.d.) 99.03± 22.21 92.17± 19.49 90.34± 18.38 121.20± 14.68
CPZE, mean (s.d.) — 445.81± 467.35 512.35± 496.69 —
rs1702294 genotype %, TT/TC/CC 2.8/29.0/65.7 2.5/29.9/67.5 2.8/30.3/66.9 4.2/28.9/66.8
Abbreviations: CPZE, chlorpromazine equivalent; FSIQ, full-scale IQ; IQ, intelligence quotient; SZ, schizophrenia; SZA, schizoaffective disorder; WAIS, Wechsler
Adult Intelligence Scale. Mean± s.d. reported.
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Whereas the risk ‘C’ allele of rs1702294 was associated with
variance on only three cognitive tests, the polygenic risk was
associated with multiple test scores in both the memory and
general cognitive domains.
Participant demographics: fMRI
Participant demographics for the fMRI spatial working memory
sample are presented in Table 4. A regression analysis was
performed in SPSS (22.0.0) to examine any signiﬁcant effects of
MIR137 pathway risk (at P= 10− 5, P= 0.05 and P= 0.5 levels) on
age, gender, years of education, SWM accuracy or SWM reaction
time in our sample. Overall, there were no signiﬁcant effects of
MIR137 pathway risk on any of these variables (P40.05).
Participant demographics for the overlapping fMRI face
processing sample are presented in Supplementary Table 5. A
regression analysis was performed in SPSS (22.0.0) to examine any
signiﬁcant effects of MIR137 pathway risk (at P= 10− 5, P= 0.05 and
P= 0.5 levels) on age, gender, or years of education, and once
again there were no signiﬁcant effects of MIR137 pathway risk on
any of these variables (P40.05).
Effects of MIR137 pathway risk score on neural activity
Increasing MIR137 pathway risk score (P= 10− 5 level) was
associated with signiﬁcantly increased neural activation in clusters
incorporating the right middle temporal gyrus, left posterior
cingulate and left thalamus with increasing spatial working
memory load (3 dots versus 1 dot contrast, Supplementary
Table 6). In each individual the mean parameters estimates of all
voxels was calculated for each cluster showing a signiﬁcant effect.
These values were then entered into SPSS to check for outliers.
Overall, three outliers were detected. As such, the analysis was run
again, excluding these individuals. When this analysis was re-run,
two clusters showed a signiﬁcant effect of increasing MIR137
pathway risk score, one incorporating the right inferior occipital
gyrus and right middle temporal gyrus, and another in the medial
parietal region (individual cluster peaks not found on any
probability maps using Anatomy toolbox). We observed that, in
the high working memory load condition (3-dot versus 1-dot)
increasing MIR137 polygenic risk score (P= 10− 5 level) was
associated with increased activation across two clusters
(Supplementary Table 6). The ﬁrst incorporated the right inferior
occipital gyrus and right middle temporal gyrus and showed peak
coordinates in the right inferior occipital gyrus (MNI peak
coordinates 48, − 76, − 2; tmax = 4.80; P-value = 0.011; cluster extent
Table 3. Linear regression analyses of rs1702294 risk allele (C) effects on cognitive test scores for all participants
Neuropsychological variable Standardized β CI P-value r2
Lower Upper
IQ
Pre-morbid IQ (WTAR) − 0.044 − 2.215 0.482 0.207 0.002
Verbal IQ − 0.046 − 4.514 0.709 0.153 0.002
Performance IQ − 0.091 − 6.701 − 1.041 0.007** 0.008
Full-scale IQ − 0.080 − 6.157 − 0.563 0.019* 0.006
DM
Logical memory 1 − 0.050 − 3.077 0.298 0.106 0.003
Logical memory 2 − 0.025 − 1.740 0.726 0.420 0.001
Faces 1 − 0.059 − 1.322 0.151 0.119 0.003
Faces 2 − 0.008 − 0.815 0.646 0.820 0.000
WM
SWM (errors) 0.031 − 1.611 4.415 0.361 0.001
SWM (strategy) 0.017 − 0.800 1.316 0.632 0.000
Letter-number sequencing − 0.032 − 0.642 0.202 0.306 0.001
Attention
SART reaction time 0.059 − 3.873 30.073 0.013* 0.003
CPT d’Prime 2 digit − 0.044 − 0.302 0.103 0.334 0.002
CPT d’Prime 3 digit − 0.031 − 0.257 0.126 0.504 0.000
CPT d’Prime 4 digit − 0.019 − 0.194 0.127 0.679 0.000
Social cognition
Eyes − 0.040 − 1.308 0.449 0.337 0.001
Hint − 0.083 − 0.972 − 0.018 0.042* 0.008
Externalizing bias 0.000 − 0.613 − 0.614 0.998 0.000
Personalizing bias 0.020 − 0.033 0.053 0.645 0.000
Abbreviations: CI, conﬁdence interval; CPT, Continuous Performance Task; DM, declarative memory; IQ, intelligence quotient; SART, Sustained Attention to
Response Task; SWM, Spatial Working Memory; WM, working memory; WTAR, Wechsler Test of Adult Reading. Results in bold indicate signiﬁcance after
correction for multiple testing across 5 cognitive domains. *Po0.05; **Po0.01; ***Po0.0001.
Table 4. Participant demographics: fMRI sample
Age 28.79± 9.05a
Gender 38 M/48 F
Years of education 17.48± 3.32b
SWM accuracy (correct trials/72) 63.59± 8.77
SWM reaction time (ms) 8737.15± 2166.99
MIR137 pathway risk score at P= 10− 5 0.047755814± 0.006577924
MIR137 pathway risk score at P= 0.05 0.022951163± 0.000631104
MIR137 pathway risk score at P= 0.5 0.014223256±0.000195643
Abbreviations: MIR137, microRNA-137; SWM, Spatial Working Memory.
aMean± s.d. reported. bEducation information available for 82 of 86
participants.
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(voxels) = 175; Figure 1). A second cluster, located in the medial
parietal region, did not localize to any known probability maps
using Anatomy toolbox (Cluster extent [voxel] = 121, P= 0.038,
tmax = 4.19; MNI peak coordinates 3, − 34, 16), possibly because
these coordinates represent a region of overlap between gray and
white matter (Figure 1). No other effects were observed either for
other MIR137 polygenic thresholds or other contrasts. Note that
neural activity associated with the 3-dot versus 1-dot condition
across all participants is presented in Supplementary Table 7 and
Figure 1, showing overlap with the right inferior occipital cluster in
which a MIR137 effect was observed.
Finally, for the face processing task, after correcting for outliers
(n= 1 using the same outlier detection method as for the spatial
working memory data) no signiﬁcant effects of the empirically
derived miR-137 regulated gene score (at P= 10− 5, P= 0.05, or
P= 0.5 levels) were observed for any other contrast.
DISCUSSION
This study assessed the effects of higher polygenic risk burden in a
network of genes whose expression was altered by manipulation
of miR-137 expression, the gene product of a SZ risk gene. On the
basis of previous studies from our group and others, we sought to
establish whether this gene network would convey the same
cognitive and cortical effects as have been associated with
individual risk variants at this locus and, if so, whether the amount
of variance explained was the same or greater. We did this based
on polygene scores derived from all risk variants within this
network (not including MIR137 risk SNPs themselves), calculated
from three risk thresholds using the PGC-SCZ1 data (P= 10− 5,
P= 0.05 and P= 0.5). Following correction for multiple testing we
found that, irrespective of the threshold used, genetic variants
within the deﬁned MIR137 score were associated with lower
declarative memory performance. We also found that the MIR137
pathway was nominally associated with poorer working memory
and general cognitive ability. Finally, functional imaging revealed
that participants showed increased cortical activation in right
inferior occipital gyrus during a spatial working memory task. This
was found in the absence of any association with cortical activity
during a face processing task and polygenic risk. Collectively,
these data indicate deleterious effects of risk variants within the
empirically derived miR-137 regulated gene score was on
cognitive function in patients and controls.
Studies seeking to characterize the cognitive effects of
individual risk variants have been criticized previously for low
power, making their ﬁndings difﬁcult to replicate. This study,
based on one of the largest single data sets available (n= 1000
individuals with adequate genetic information available from a
total of 1269 participants collected) attempted to overcome this
difﬁculty through the use of a relatively large sample size and a
novel approach to risk—that is, calculated on the basis of a risk
gene molecular pathway. The robustness of our results are
supported by the following: (1) the direction of all signiﬁcant
results were the same both for the full dataset and when both the
narrow and broad patients groups were analyzed alone; (2) the
ﬁndings were consistent across all genetic risk thresholds, even
after correction for the number of cognitive functions assessed
(general cognitive ability, declarative memory, working memory,
attentional control, and social cognition) was made; (3) in the
case of the memory subtests used, ﬁndings replicated across
Figure 1. Effect of increasing MIR137 pathway risk score (P= 10− 5 level) on neural activity during increasing spatial working memory load (3
dots versus 1 dot), 3 outliers removed (N= 83; shown in red), shown alongside overall activation for this contrast in the same group (shown in
blue). Cluster 1 (right inferior occipital gyrus and right middle temporal gyrus), top panels; Cluster 2 (medial parietal region) bottom panels.
Clusters are signiﬁcant at Po0.05, FWE-corrected at the cluster level and represent regions where neural activity was greater with increasing
risk score. Each 2D axial slice is labeled with an x-coordinate (MNI space). Clusters are rendered on the ‘ch256’ brain template using MRIcroGL
(http://www.mccauslandcenter.sc.edu/mricrogl/). Additional editing of ﬁgure (for example, changing the size/resolution) performed using MS
Paint and/or Paint.NET v3.5.10. FWE, family-wise error; MIR137, microRNA-137; MNI, Montreal Neurological Institute.
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modalities, that is, increased polygenic risk was associated with
both poorer verbal performance and poorer non-verbal perfor-
mance; ﬁnally, (4) the amount of variation in cognitive perfor-
mance explained by the empirically derived miR-137 regulated
gene score was larger than that explained by the single MIR137
variant, rs1702294, with the polygenic pathway score explaining in
the region of ~ 2% (Supplementary Table 1) of variance on
declarative memory measures. Although still modest, this is
approximately two to three times the variance explained by the
individual rs1702294 SNP.
Although correction for multiple testing was carried out for the
cognitive component of the study (a Bonferroni correction for ﬁve
domains: IQ, working memory, visual declarative memory,
attention and social cognition) we did not correct for the fact
that three polygenic risk signiﬁcance thresholds were used. It is
still unclear what the best approach to selecting thresholds is. The
original PGC analysis3 reported 10 risk thresholds. We have
included three to reduce the multiple testing burden, while others
have reduced this burden even further by including only one, for
example, a threshold of P= 0.5.50 However, for our cognitive
analysis the threshold considered would appear to have been
unimportant: broadly the same cognitive associations were
observed for each of the three thresholds considered. This would
suggest that in fact a study of only one threshold would have
been sufﬁcient to characterize the cognitive consequences of this
gene set. For the neuroimaging study, an association between
MIR137 polygenic risk and cortical activation during a working
memory task was only signiﬁcant at the most conservative
threshold of P= 10− 5; why this might have been case is uncertain.
One possibility is that this was simply a false-positive ﬁnding; the
fact that only a subsample of participants were included in this
analysis, albeit relatively large for fMRI studies (n= 108) might
support this conclusion. Other explanations include that imaging
ﬁndings may be more sensitive to the signal to noise ratio
inherent in high polygenic risk thresholds (that is, that more
lenient thresholds harbor a greater percentage of variants not
robustly associated with risk, hence making them less informa-
tive). To our knowledge, only one other polygenic fMRI study has
been carried out to date, and as noted included only one
threshold.50 As a consequence this relatively novel approach
requires the accumulation of further studies to determine the best
thresholding approach to take, as evidence for an optimum
threshold (in terms of signal to noise ratio) has yet to emerge.
When examining brain regions showing increased blood
oxygenation level dependent (BOLD) response with increasing
spatial working memory load (contrast: 3 dots condition41 dot
condition), two clusters showed signiﬁcantly increased BOLD
response in individuals with higher MIR137 pathway risk score
(MIR137 pathway risk score P= 10− 5 level). The ﬁrst cluster
incorporated the right inferior occipital gyrus and right middle
temporal gyrus. Given that this cluster overlaps with cortical
regions activated by our task (Figure 1), hyperactivation in this
cluster may represent relative inefﬁciency in processing task
stimuli in individuals with higher risk scores, although this
suggestion remains speculative.
Although a second cluster, in the medial parietal region,
showed signiﬁcantly increased BOLD response with increasing
MIR137 pathway risk score (P= 10− 5 level) also, no individual peak
coordinates in MNI space were not found on any probability map
(Figure 1). Given that visual inspection of this cluster reveals that a
large proportion resides in white matter, this may be an
artefactual ﬁnding and should be interpreted with caution. It is
possible that as regions of the medial parietal cortex typically
show task-induced decreases in BOLD response,51 the present
ﬁnding of increased BOLD response in this region may relate to a
relative failure to deactivate this region during the working
memory task in individuals with higher risk scores. However, as
noted above, the fact that these results are obtained in a sample
that, although large for imaging studies, is quite modest for
genetics studies, requires caution in interpretation of these results.
In addition to the issue of sample size, further study limitations
include that only healthy participants were used for studying the
association of polygenic risk on patterns of brain activation. Ideally
the analysis will be repeated in a patient sample to conﬁrm
ﬁndings in this group. However, symptoms in SZ and cognitive
deﬁcits occur along a spectrum, so despite the lack of patient fMRI
data, our current analysis does allow for investigation of the
association between this polygene score and functional altera-
tions in healthy participant endophenotypes. In addition, a recent
paper evaluating the effect of MIR137 on gray matter concentra-
tion found that the effects of SNPs in MIR137 and associated
pathways have greater impact on brain structure and function in
SZ patients than healthy participants.52 The results of the present
analysis of healthy participants may be indicative of a greater
impact in a patient population. Another potential limitation here is
using a gene list derived from human progenitor neural cells, in
which the stability of transcriptional regulation can change over
time. Nonetheless, at least some of the genetic variants identiﬁed
to generate the polygenic score are present in both adult and
embryonic stages, so the effect of the variant may have already
had its substantial inﬂuence in neurodevelopmental stages. With
regard to the effect of medication on cognition, medication
dosage was not used as a covariate in our whole sample analysis,
which included controls, as doing so would have limited our
sample size in the analysis (n= 1000) to patients with this
information (n= 585). In the patient groups considered separately,
results from the neuropsychological results were non-signiﬁcant
following Bonferroni correction; including medication dosage as a
covariate in this analysis did not change these results.
Taking a polygene approach to characterize genetic effects has
particular signiﬁcance for the MIR137 polygene score. As with
other gene sets and putative biological pathways, discrepancies
exist between genes that are bioinformatically predicted to be
related, and those that have been empirically identiﬁed. For the
MIR137 polygene scores generated here, we included only
empirically derived genes. Gene expression changes in this study
were found to signiﬁcantly correlate with those following miR-137
manipulation in another human neural progenitor cell line in the
subsequent study.21 Several lines of evidence suggest that at least
part of the risk for SZ conferred by genetic variation at the MIR137
locus is via effects of miR-137 perturbation on the expression of
other SZ susceptibility genes.1,15,20,53 Thus, variants within this
empirically derived miR-137 regulated gene score that contribute
to SZ polygenic risk may be hypothesized to impact upon
cognitive function that is a central feature of the disorder. This
study, by charactering the cumulative polygenic effects of these
downstream risk variants while excluding the effects of risk
variants with the miR-137 gene itself supports this hypothesis,
both at a cognitive and at a cortical level. Functional studies
indicate that miR-137 is involved in proliferation, migration and
maturation of neural cells,6–8 likely to be the mechanisms behind
this involvement with the cognitive process. Further studies of the
effects of MIR137 polygene scores may beneﬁt from adopting a
more ﬁne-grained approach to the selection of SNPs. This could
include parsing the effects on cognition of those variants in this
network that are directly versus indirectly inﬂuenced by MIR137,
given that both are likely to have been included in the gene set.15
This was not possible in this study as the method of gene
selection could not differentiate between direct and indirect
interactors of MIR137.
In conclusion, these data suggest that increased polygenic risk
in a gene set consisting of downstream targets of miR-137 was
associated with decreased cognitive performance, both in terms
of memory function, and for general cognitive ability. Notably, the
strength of association was stronger for the gene set as a whole
than for the most strongly associated MIR137 SNP. These data are
Polygenic MiR-137 pathway and cognition
D Cosgrove et al
7
Translational Psychiatry (2017), 1 – 9
consistent with emerging evidence that at least some of the
genetic risk for SZ conferred by MIR137 variation relates to its
downstream effects on gene expression.
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